BTNL2 and neoplasm: Strikingly, both intraperitoneal (i.p.)and intravenous (i.v.)delivery of anti-BTNL2 mAb to tumour-bearing mice significantly reduced Lewis lung cancer (LLC) tumour growth (Fig. 1a).